Data from Almirall, Forest Labs' aclidinium studies on COPD to be presented at ... News-Medical.net Aclidinium bromide is a new, inhaled long-acting antimuscarinic agent currently under review by the FDA for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). The poster discussion titled "Long-Term Efficacy And Safety of ... and more » |
Phase 2 Results for EP-101 Positive Drug Discovery & Development Patients with moderate to severe COPD treated with EP-101 after seven days had a clinically meaningful and statistically significant improvement in lung function versus placebo. EP-101 is a proprietary inhalation solution formulation of glycopyrrolate, ... and more » |
Forest and Almirall to Present Aclidinium Bromide Clinical Data at the ... MarketWatch (press release) Aclidinium bromide is a new, inhaled long-acting antimuscarinic agent currently under review by the FDA for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). The poster discussion titled "Long-Term Efficacy And Safety of ... and more » |
Novartis to present positive phase III GLOW2 study data at 2012 ATS conference pharmabiz.com “The GLOW2 results affirm the potential for once-daily NVA237 to help patients manage their COPD symptoms and improve their quality of life,” said Tim Wright, Head of Development, Novartis Pharmaceuticals. “Novartis is committed to addressing the unmet ... Novartis NVA237 Phase III data showed rapid, sustained improvement in lung ...PharmiWeb.com (press release) Novartis-Vectura COPD boostBusiness Weekly NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International ...PR Newswire (press release) all 7 news articles » |
 MD News | Accupuncture Could Be An Effective Treatment For COPD RTT News Researchers provided 68 COPD patients with acupuncture along with their regular medications over the course of three months. At the end of the trial, they found that those patients were able to walk with greater ease of breath than those who received a ... Study: Acupuncture may help some people with COPDFox News Acupuncture Helps With COPD, Study FindsHuffington Post Acupuncture improved dyspnea on exertion in COPDClinical Advisor Los Angeles Times -Natural Standard Blog (blog) all 22 news articles » |
Glaxo Hikes Stake in Theravance Zacks.com Glaxo intends to seek approval for Relovair in the US and Europe in mid-2012 for the COPD indication. The pharma giant also intends to seek European approval of the drug for treating asthma patients in mid-2012. Regarding the US approval of Relovair ... GSK completes acquisition of 10 million shares to increase ownership in Theravancepharmabiz.com GSK pays $213 million to raise stake in Theravance to 26.7%Pharma Times all 10 news articles » |
 Mother Nature Network (blog) | Acupuncture improved dyspnea on exertion in COPD Clinical Advisor HealthDay News -- Acupuncture appears to improve dyspnea during exertion in patients with chronic obstructive pulmonary disease (COPD), study findings show. Patients treated with acupuncture in a small randomized trial experienced less shortness of ... Study: Acupuncture may help some people with COPDFox News Acupuncture Helps With COPD, Study FindsHuffington Post Could patients with COPD breathe easier with acupuncture?Los Angeles Times Mother Nature Network (blog) -Health.com all 16 news articles » |
Novartis NVA237 Phase III data showed rapid, sustained improvement in lung ... Reuters Novartis International AG / Novartis NVA237 Phase III data showed rapid, sustained improvement in lung function and symptom relief over one year in COPD patients . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for ... Novartis' COPD drug clears phase III trialPMLiVE Novartis lung drug superior to placebo over 1 yearFox News Novartis says NVA237 Phase III study met primary endpoint in COPD patientsRTT News MarketWatch (press release) all 31 news articles » |
Novartis Says NVA237 Phase III Study Met Primary Endpoint In COPD Patients RTT News "The GLOW2 results affirm the potential for once-daily NVA237 to help patients manage their COPD symptoms and improve their quality of life," said Tim Wright, Head of Development, Novartis Pharmaceuticals. "Novartis is committed to addressing the unmet ... Novartis lung drug superior to placebo over 1 yearFox News Novartis-Vectura COPD boostBusiness Weekly NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International ...PR Newswire (press release) PharmiWeb.com (press release) all 8 news articles » |
Novartis NVA237 Phase III data showed rapid, sustained improvement in lung ... MarketWatch (press release) Basel, Switzerland, May 17, 2012 (Thomson Reuters ONE via COMTEX) -- Novartis International AG / Novartis NVA237 Phase III data showed rapid, sustained improvement in lung function and symptom relief over one year in COPD patients . Novartis' COPD drug clears phase III trialPMLiVE New Novartis COPD drug beats placebo over a yearPharma Times NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International ...Sacramento Bee all 35 news articles » |